No headlines found.
National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
ACCESS Newswire (Thu, 13-Nov 8:30 AM ET)
Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Dsseldorf
ACCESS Newswire (Thu, 6-Nov 4:01 PM ET)
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results
ACCESS Newswire (Tue, 4-Nov 8:56 AM ET)
Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals
ACCESS Newswire (Tue, 14-Oct 8:30 AM ET)
ACCESS Newswire (Tue, 7-Oct 8:30 AM ET)
ACCESS Newswire (Thu, 25-Sep 4:01 PM ET)
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Sonoma Pharmaceuticals trades on the NASDAQ stock market under the symbol SNOA.
As of December 17, 2025, SNOA stock price climbed to $3.55 with 41,733 million shares trading.
SNOA has a beta of 1.82, meaning it tends to be more sensitive to market movements. SNOA has a correlation of 0.07 to the broad based SPY ETF.
SNOA has a market cap of $6.04 million. This is considered a Sub-Micro Cap stock.
Last quarter Sonoma Pharmaceuticals reported $6 million in Revenue and -$.32 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.01.
In the last 3 years, SNOA traded as high as $53.60 and as low as $1.75.
The top ETF exchange traded funds that SNOA belongs to (by Net Assets): VXF.
SNOA has outperformed the market in the last year with a price return of +34.0% while the SPY ETF gained +11.8%. However, in the short term, SNOA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.5% vs +2.0% return in SPY. But in the last 2 weeks, SNOA shares have fared better than the market returning +12.0% compared to SPY -1.5%.
SNOA support price is $3.14 and resistance is $3.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNOA shares will trade within this expected range on the day.